Clinical Trials Logo

Clinical Trial Summary

Primary mucosal melanomas (MPM) are rarer than cutaneous melanomas, but also more severe. They are usually refractory to conventional approaches, regularly excluded from major therapeutic programs and not sensitive to new targeted therapies orphans. " The identification of therapeutic targets and accessibility to existing, developing or future targeted therapies improves the survival of patients with MPM.

The principal goal is to describe, using a large panel of genes, the prevalence of major mutations in a cohort of MPMs based on the population of a French region.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03319693
Study type Observational
Source CHU de Reims
Contact
Status Active, not recruiting
Phase
Start date August 28, 2017
Completion date April 28, 2021

See also
  Status Clinical Trial Phase
Completed NCT01961115 - Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Phase 2
Active, not recruiting NCT03241186 - Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Phase 2
Withdrawn NCT05482074 - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Phase 2
Completed NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Completed NCT04551352 - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Phase 1
Active, not recruiting NCT03033576 - Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma Phase 2
Terminated NCT01166126 - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Phase 2
Completed NCT02158520 - Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Phase 2
Withdrawn NCT03220009 - Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Phase 2
Recruiting NCT05628883 - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Phase 1
Active, not recruiting NCT03178123 - The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery Phase 2
Recruiting NCT04462965 - Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study Phase 2
Recruiting NCT04830124 - Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 Phase 2
Not yet recruiting NCT06424626 - A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma Phase 1
Completed NCT00085189 - Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Phase 2
Recruiting NCT05384496 - Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Phase 2
Recruiting NCT06319196 - Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Phase 2
Completed NCT02126579 - Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Phase 1/Phase 2
Not yet recruiting NCT05545969 - Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma Phase 2
Recruiting NCT03986515 - Apatinib Plus SHR1210 in Advanced Mucosal Melanoma Phase 2